{"elapsedTime":614,"returnCode":0,"statusMessage":null,"maxPartsAvailable":4,"partResults":[{"elapsedTime":235,"identifier":"0","package":{"portalHeadlineListDataResult":{"hitCount":{"displayText":{"value":"3"},"value":3},"resultSet":{"count":{"displayText":{"value":"3"},"value":3},"duplicateCount":{"displayText":{"value":"0"},"value":0},"first":{"displayText":{"value":"0"},"value":0},"headlines":[{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"19 April 2011","modificationDateTime":"\/Date(1303171200000)\/","modificationDateTimeDescriptor":"19 April 2011","modificationTimeDescriptor":"2:01","publicationDateDescriptor":"19 April 2011","publicationDateTime":"\/Date(1303192860000)\/","publicationDateTimeDescriptor":"19 April 2011 2:01","publicationTimeDescriptor":"2:01","reference":{"externalUri":null,"guid":"HUGNEN0020110419e74j0005l","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Novartis International AG \/ Novartis makes strong start for the year . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. "],"sourceCode":"hugnen","sourceDescriptor":"Hugin Press Release","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Novartis makes strong start for the year ","toolTip":null,"truncatedTitle":"Novartis makes strong start for the year","wordCount":{"displayText":{"value":"12,741"},"value":12741},"wordCountDescriptor":"12,741 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"14 April 2011","modificationDateTime":"\/Date(1302739200000)\/","modificationDateTimeDescriptor":"14 April 2011","modificationTimeDescriptor":"18:09","publicationDateDescriptor":"14 April 2011","publicationDateTime":"\/Date(1302818961000)\/","publicationDateTimeDescriptor":"14 April 2011 18:09","publicationTimeDescriptor":"18:09","reference":{"externalUri":null,"guid":"LBA0000020110414e74e001md","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["* Indonesia part of wide consensus but U.S. nod awaited * Drug industry said on board to share costs of helping poor  By Stephanie Nebehay  GENEVA, April 14 (Reuters) - A global deal is tantalisingly\u000aclose under which countries would share ... "],"sourceCode":"lba","sourceDescriptor":"Reuters News","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Deal in reach on flu virus-sharing, vaccine access ","toolTip":null,"truncatedTitle":"Deal in reach on flu virus-sharing, vaccine access","wordCount":{"displayText":{"value":"523"},"value":523},"wordCountDescriptor":"523 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"16 April 2011","modificationDateTime":"\/Date(1302912000000)\/","modificationDateTimeDescriptor":"16 April 2011","modificationTimeDescriptor":"1:19","publicationDateDescriptor":"16 April 2011","publicationDateTime":"\/Date(1302931152000)\/","publicationDateTimeDescriptor":"16 April 2011 1:19","publicationTimeDescriptor":"1:19","reference":{"externalUri":null,"guid":"LBA0000020110416e74g0002p","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["* Paves way for sharing flu virus in exchange for vaccines * Draft deal being sent to ministers for approval in May * IFPMA welcomes accord and confirms details to Reuters "],"sourceCode":"lba","sourceDescriptor":"Reuters News","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"UPDATE 2 -Big Pharma backs deal to boost flu pandemic readiness ","toolTip":null,"truncatedTitle":"UPDATE 2 -Big Pharma backs deal to boost flu pandemic readiness","wordCount":{"displayText":{"value":"638"},"value":638},"wordCountDescriptor":"638 words"}]}},"title":"Bird Flu","viewAllSearchContext":"{\"pn\":\"NP\",\"sct\":\"CustomTopicsViewAllSearchContext\",\"j\":\"{\\\"cti\\\":0,\\\"ctn\\\":null}\",\"pid\":\"13548\",\"mid\":\"22505\"}"},"packageType":"CustomTopicsPackage","returnCode":0,"statusMessage":null},{"elapsedTime":266,"identifier":"1","package":{"portalHeadlineListDataResult":{"hitCount":{"displayText":{"value":"83"},"value":83},"resultSet":{"count":{"displayText":{"value":"5"},"value":5},"duplicateCount":{"displayText":{"value":"1"},"value":1},"first":{"displayText":{"value":"0"},"value":0},"headlines":[{"authors":["By Ann Lukits "],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":false,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"19 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"0:00","publicationDateDescriptor":null,"publicationDateTime":"\/Date(1303171200000)\/","publicationDateTimeDescriptor":"19 April 2011","publicationTimeDescriptor":null,"reference":{"externalUri":null,"guid":"WSJO000020110418e74j00bf6","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Researchers have developed a new vaccine to desensitize people with a cat allergy that is faster and safer than traditional immunotherapies, according to a study in the Journal of Allergy and Clinical Immunology. Cat allergy affects up to ... "],"sourceCode":"wsjo","sourceDescriptor":"The Wall Street Journal Online","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Cutting Allergy Shots ","toolTip":null,"truncatedTitle":"Cutting Allergy Shots","wordCount":{"displayText":{"value":"1,395"},"value":1395},"wordCountDescriptor":"1,395 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"website","contentSubCategoryDescriptor":"webpage","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"17 April 2011","modificationDateTime":"\/Date(1302998400000)\/","modificationDateTimeDescriptor":"17 April 2011","modificationTimeDescriptor":"17:37","publicationDateDescriptor":"17 April 2011","publicationDateTime":"\/Date(1303076220000)\/","publicationDateTimeDescriptor":"17 April 2011 17:37","publicationTimeDescriptor":"17:37","reference":{"externalUri":null,"guid":"WC51453020110417e74h000xd","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["The National Cancer Institute (NCI) maintains and regularly updates library that provides information on the effectiveness of \"alternative and complementary treatments,\" or ACT's. Versions for professionals and the general public are ... "],"sourceCode":"wc51453","sourceDescriptor":"Defamer","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Joseph Nowinski, Ph.D.: Alternative and Complementary Treatments for Cancer ","toolTip":null,"truncatedTitle":"Joseph Nowinski, Ph.D.: Alternative and Complementary Treatments for Cancer","wordCount":{"displayText":{"value":"1,266"},"value":1266},"wordCountDescriptor":"1,266 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"website","contentSubCategoryDescriptor":"webpage","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"17 April 2011","modificationDateTime":"\/Date(1302998400000)\/","modificationDateTimeDescriptor":"17 April 2011","modificationTimeDescriptor":"17:27","publicationDateDescriptor":"17 April 2011","publicationDateTime":"\/Date(1303075620000)\/","publicationDateTimeDescriptor":"17 April 2011 17:27","publicationTimeDescriptor":"17:27","reference":{"externalUri":null,"guid":"WC46902020110417e74h000xf","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Last week saw the release of a very important new resource for medical providers serving transsexual and gender-variant patients. The Primary Care Protocol for Transgender Patient Care is a web-based resource that goes beyond hormone ... "],"sourceCode":"wc46902","sourceDescriptor":"Huffington Post","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Joanne Herman: A New Tool for Treating Transgender People ","toolTip":null,"truncatedTitle":"Joanne Herman: A New Tool for Treating Transgender People","wordCount":{"displayText":{"value":"659"},"value":659},"wordCountDescriptor":"659 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"18 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"6:05","publicationDateDescriptor":"18 April 2011","publicationDateTime":"\/Date(1303121115000)\/","publicationDateTimeDescriptor":"18 April 2011 6:05","publicationTimeDescriptor":"6:05","reference":{"externalUri":null,"guid":"LBA0000020110418e74i000mu","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["(Repeats April 15 story with no changes to text) * Says EU market for device is over $3 bln * Expects to have maximum penetration in 3-5 years "],"sourceCode":"lba","sourceDescriptor":"Reuters News","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"RPT-INTERVIEW-Delcath to launch liver cancer device by end-2011- CEO ","toolTip":null,"truncatedTitle":"RPT-INTERVIEW-Delcath to launch liver cancer device by end-2011- CEO","wordCount":{"displayText":{"value":"394"},"value":394},"wordCountDescriptor":"394 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"18 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"4:22","publicationDateDescriptor":"18 April 2011","publicationDateTime":"\/Date(1303114920000)\/","publicationDateTimeDescriptor":"18 April 2011 4:22","publicationTimeDescriptor":"4:22","reference":{"externalUri":null,"guid":"DTMNTR0020110418e74i0002a","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["EDAP TMS SA, a medical device company, has announced E1.1 million from European Union's Eurostars Program to the consortium research cooperation program comprised of project leader Epitarget AS, a Norwegian Company, French academic ... "],"sourceCode":"dtmntr","sourceDescriptor":"Datamonitor News and Comment","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"EDAP announces E1.1 million grant for drug delivery program ","toolTip":null,"truncatedTitle":"EDAP announces E1.1 million grant for drug delivery program","wordCount":{"displayText":{"value":"218"},"value":218},"wordCountDescriptor":"218 words"}]}},"title":"Cancer","viewAllSearchContext":"{\"pn\":\"NP\",\"sct\":\"CustomTopicsViewAllSearchContext\",\"j\":\"{\\\"cti\\\":1,\\\"ctn\\\":null}\",\"pid\":\"13548\",\"mid\":\"22505\"}"},"packageType":"CustomTopicsPackage","returnCode":0,"statusMessage":null},{"elapsedTime":235,"identifier":"2","package":{"portalHeadlineListDataResult":{"hitCount":{"displayText":{"value":"63"},"value":63},"resultSet":{"count":{"displayText":{"value":"5"},"value":5},"duplicateCount":{"displayText":{"value":"0"},"value":0},"first":{"displayText":{"value":"0"},"value":0},"headlines":[{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"19 April 2011","modificationDateTime":"\/Date(1303171200000)\/","modificationDateTimeDescriptor":"19 April 2011","modificationTimeDescriptor":"2:01","publicationDateDescriptor":"19 April 2011","publicationDateTime":"\/Date(1303192860000)\/","publicationDateTimeDescriptor":"19 April 2011 2:01","publicationTimeDescriptor":"2:01","reference":{"externalUri":null,"guid":"HUGNEN0020110419e74j0005l","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Novartis International AG \/ Novartis makes strong start for the year . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. "],"sourceCode":"hugnen","sourceDescriptor":"Hugin Press Release","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Novartis makes strong start for the year ","toolTip":null,"truncatedTitle":"Novartis makes strong start for the year","wordCount":{"displayText":{"value":"12,741"},"value":12741},"wordCountDescriptor":"12,741 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"19 April 2011","modificationDateTime":"\/Date(1303171200000)\/","modificationDateTimeDescriptor":"19 April 2011","modificationTimeDescriptor":"3:42","publicationDateDescriptor":"19 April 2011","publicationDateTime":"\/Date(1303198962000)\/","publicationDateTimeDescriptor":"19 April 2011 3:42","publicationTimeDescriptor":"3:42","reference":{"externalUri":null,"guid":"HUGNEN0020110419e74j000dx","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Investigator-initiated European multicenter trial of 1,000 acute heart attack patients will examine the ability of cyclosporine to protect cardiac tissue "],"sourceCode":"hugnen","sourceDescriptor":"Hugin Press Release","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"First Heart Attack Patient Treated in European Cardioprotection Phase III trial with NeuroVive's CicloMulsion[TM] ","toolTip":null,"truncatedTitle":"First Heart Attack Patient Treated in European Cardioprotection Phase III trial...","wordCount":{"displayText":{"value":"973"},"value":973},"wordCountDescriptor":"973 words"},{"authors":["By Ann Lukits "],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":false,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"19 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"0:00","publicationDateDescriptor":null,"publicationDateTime":"\/Date(1303171200000)\/","publicationDateTimeDescriptor":"19 April 2011","publicationTimeDescriptor":null,"reference":{"externalUri":null,"guid":"WSJO000020110418e74j00bf6","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Researchers have developed a new vaccine to desensitize people with a cat allergy that is faster and safer than traditional immunotherapies, according to a study in the Journal of Allergy and Clinical Immunology. Cat allergy affects up to ... "],"sourceCode":"wsjo","sourceDescriptor":"The Wall Street Journal Online","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Cutting Allergy Shots ","toolTip":null,"truncatedTitle":"Cutting Allergy Shots","wordCount":{"displayText":{"value":"1,395"},"value":1395},"wordCountDescriptor":"1,395 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"18 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"7:53","publicationDateDescriptor":"18 April 2011","publicationDateTime":"\/Date(1303127639000)\/","publicationDateTimeDescriptor":"18 April 2011 7:53","publicationTimeDescriptor":"7:53","reference":{"externalUri":null,"guid":"LBA0000020110418e74i000t5","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["(Repeating item that initially moved on Saturday) * Blood-clotting rate more than 9 pct per patient year * Higher than doctors or Wall Street expected "],"sourceCode":"lba","sourceDescriptor":"Reuters News","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"RPT-HeartWare device had 9.2% thrombosis rate in trial ","toolTip":null,"truncatedTitle":"RPT-HeartWare device had 9.2% thrombosis rate in trial","wordCount":{"displayText":{"value":"930"},"value":930},"wordCountDescriptor":"930 words"},{"authors":[],"baseLanguage":"en","baseLanguageDescriptor":"English","contentCategoryDescriptor":"publication","contentSubCategoryDescriptor":"article","hasPublicationTime":true,"headlineUrl":null,"mediaLength":null,"modificationDateDescriptor":"18 April 2011","modificationDateTime":"\/Date(1303084800000)\/","modificationDateTimeDescriptor":"18 April 2011","modificationTimeDescriptor":"1:58","publicationDateDescriptor":"18 April 2011","publicationDateTime":"\/Date(1303106280000)\/","publicationDateTimeDescriptor":"18 April 2011 1:58","publicationTimeDescriptor":"1:58","reference":{"externalUri":null,"guid":"DTMNTR0020110418e74i0002p","mimetype":"text\/xml","ref":null,"type":"accessionNo"},"snippets":["Proteon Therapeutics, Inc., a biopharmaceutical company, has initiated enrollment in a Phase II clinical study of its lead product, PRT-201, in chronic kidney disease, or CKD, patients undergoing surgery for arteriovenous fistula, or AVF, ... "],"sourceCode":"dtmntr","sourceDescriptor":"Datamonitor News and Comment","thumbnailImage":{"guid":null,"src":null,"uri":null},"title":"Proteon Therapeutics initiates Phase II chronic kidney disease study ","toolTip":null,"truncatedTitle":"Proteon Therapeutics initiates Phase II chronic kidney disease study","wordCount":{"displayText":{"value":"306"},"value":306},"wordCountDescriptor":"306 words"}]}},"title":"Official Trials\/Tests","viewAllSearchContext":"{\"pn\":\"NP\",\"sct\":\"CustomTopicsViewAllSearchContext\",\"j\":\"{\\\"cti\\\":2,\\\"ctn\\\":null}\",\"pid\":\"13548\",\"mid\":\"22505\"}"},"packageType":"CustomTopicsPackage","returnCode":120,"statusMessage":null}]}